Sign In
Buy ANVS
$1.77
+0.0200 (+1.14%)
At Close: Jun 22, 2026
Annovis Bio Regains NYSE Listing Compliance
08:00am, Tuesday, 26'th May 2026
MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral t
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
08:00am, Wednesday, 20'th May 2026
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral t
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
04:06pm, Tuesday, 19'th May 2026
MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral t
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
07:30am, Friday, 15'th May 2026
Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026 PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026 New D
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
07:30am, Thursday, 07'th May 2026
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral t
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
08:00am, Tuesday, 28'th Apr 2026
Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-t
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
08:30am, Friday, 10'th Apr 2026
MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
08:30am, Thursday, 09'th Apr 2026
MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral
Michael Hoffman Acquires 713,800 Shares of Annovis Bio (NYSE:ANVS) Stock
04:50am, Sunday, 05'th Apr 2026
Annovis Bio, Inc. (NYSE: ANVS - Get Free Report) Director Michael Hoffman bought 713,800 shares of the firm's stock in a transaction on Thursday, April 2nd. The stock was acquired at an average price
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
07:30am, Thursday, 02'nd Apr 2026
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral
Annovis Publishes Historical Review of Buntanetap in The Scientist
08:00am, Tuesday, 31'st Mar 2026
MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
07:30am, Thursday, 19'th Mar 2026
NeuroRPM's AI-enabled Apple Watch-based platform will provide continuous digital biomarker monitoring in Annovis Bio's Parkinson's disease clinical trial.
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
07:30am, Thursday, 19'th Mar 2026
MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
07:30am, Monday, 16'th Mar 2026
MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
08:00am, Tuesday, 03'rd Mar 2026
MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral
